Patrys Ltd
ASX:PAB

Watchlist Manager
Patrys Ltd Logo
Patrys Ltd
ASX:PAB
Watchlist
Price: 0.026 AUD Market Closed
Market Cap: 8.9m AUD

Net Margin
Patrys Ltd

-363.7%
Current
-251%
Average
-6.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-363.7%
=
Net Income
-3m
/
Revenue
828.5k

Net Margin Across Competitors

No Stocks Found

Patrys Ltd
Glance View

Market Cap
8.9m AUD
Industry
Biotechnology

Patrys Ltd. engages in the commercialisation of the group's proprietary technologies to develop natural human antibody-based therapeutic products for the treatment of cancer and the pursuit of non-dilutive funding sources. The company is headquartered in South Melbourne, Victoria. The company went IPO on 2007-07-13. The firm is engaged in developing the treatment of Glioblastoma (GBM) and Triple Negative Breast Cancer (TNBC). The firm has developed two forms of deoxymab 3E10, including PAX-DX1 and PAT-DX3. Its is also using the PAT-DX1 antibody to deliver nanoparticles carrying therapeutic payloads to the inside of cells. The firm is in the process of the first human clinical trial of PAT-DX1. Its two product candidates, PAT-DX2 and PAT-DX1-NP are under preclinical stage.

PAB Intrinsic Value
0.03 AUD
Undervaluation 15%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-363.7%
=
Net Income
-3m
/
Revenue
828.5k
What is the Net Margin of Patrys Ltd?

Based on Patrys Ltd's most recent financial statements, the company has Net Margin of -363.7%.

Back to Top